[Guangshengtang: becoming a license holder for listing of dapoxetine Hydrochloride tablets]-- Guangshengtang announced that it received a "notice of approval for supplementary drug application" issued by the State Drug Administration on dapoxetine hydrochloride tablets, agreeing that the company should act as the market license holder of the above-mentioned drugs. Dapoxetine hydrochloride tablets are first-line therapeutic drugs recommended by domestic and foreign "guidelines for the diagnosis and treatment of premature ejaculation" and other drug guidelines.